| Mountain Home Therapy | |
|
227 Mount Alice Ct, Livermore, CO 80536-8774 | |
| (970) 294-2646 | |
| Not Available |
| Full Name | Mountain Home Therapy |
|---|---|
| Type | Facility |
| Speciality | Occupational Therapist |
| Location | 227 Mount Alice Ct, Livermore, Colorado |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1730851106 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225X00000X | Occupational Therapist | (* (Not Available)) | Primary |
| Provider Name | Regina Ann Scott |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1063544005 PECOS PAC ID: 1557752656 Enrollment ID: I20211228001931 |
News Archive
Isis Pharmaceuticals, Inc. today provided an update on children with spinal muscular atrophy (SMA) who have completed the open-label, Phase 2 multiple-dose study of ISIS-SMN Rx and are continuing to receive treatment in an open-label extension (OLE) study.
In a recent development a team of 30 Spanish surgeons have succeeded in a World's first full face transplant. The patient had accidentally injured a large part of his face with a shotgun five years ago. This had left him disfigured an unable to breathe, swallow or talk properly. He has undergone nine unsuccessful operations before this operation was planned. In this operation he received the whole of his facial skin, muscles, nose, lips, teeth and cheek bones from a donor in a 22 hour operation at the Vall d'Hebron University Hospital on 20th March. He is on his way to recovery now. This is not the first face transplant but the first full face transplant and also the most complex of its kind.
Aperio Technologies, Inc., (Aperio), a global leader in digital pathology for the healthcare and life sciences industry, and HistoRx, Inc., (HistoRx), a leader in the emerging field of tissue-based assays for targeted patient treatment, have entered into a partnership to provide an integrated solution for whole-slide imaging with fluorescence.
Teva Pharmaceutical Industries Ltd. and OncoGenex Pharmaceuticals, Inc. announced today that they have entered into a global license and collaboration agreement to develop and commercialize OGX-011, as well as an agreement to purchase shares in OncoGenex. OGX-011 is a Phase III cancer therapy designed to inhibit cancer treatment resistance.
› Verified 4 days ago
| Provider Name | Nancy Rangel |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1992825525 PECOS PAC ID: 7517060148 Enrollment ID: I20240126002815 |
News Archive
Isis Pharmaceuticals, Inc. today provided an update on children with spinal muscular atrophy (SMA) who have completed the open-label, Phase 2 multiple-dose study of ISIS-SMN Rx and are continuing to receive treatment in an open-label extension (OLE) study.
In a recent development a team of 30 Spanish surgeons have succeeded in a World's first full face transplant. The patient had accidentally injured a large part of his face with a shotgun five years ago. This had left him disfigured an unable to breathe, swallow or talk properly. He has undergone nine unsuccessful operations before this operation was planned. In this operation he received the whole of his facial skin, muscles, nose, lips, teeth and cheek bones from a donor in a 22 hour operation at the Vall d'Hebron University Hospital on 20th March. He is on his way to recovery now. This is not the first face transplant but the first full face transplant and also the most complex of its kind.
Aperio Technologies, Inc., (Aperio), a global leader in digital pathology for the healthcare and life sciences industry, and HistoRx, Inc., (HistoRx), a leader in the emerging field of tissue-based assays for targeted patient treatment, have entered into a partnership to provide an integrated solution for whole-slide imaging with fluorescence.
Teva Pharmaceutical Industries Ltd. and OncoGenex Pharmaceuticals, Inc. announced today that they have entered into a global license and collaboration agreement to develop and commercialize OGX-011, as well as an agreement to purchase shares in OncoGenex. OGX-011 is a Phase III cancer therapy designed to inhibit cancer treatment resistance.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mountain Home Therapy Po Box 118, Livermore, CO 80536-0118 Ph: (970) 294-2646 | Mountain Home Therapy 227 Mount Alice Ct, Livermore, CO 80536-8774 Ph: (970) 294-2646 |
News Archive
Isis Pharmaceuticals, Inc. today provided an update on children with spinal muscular atrophy (SMA) who have completed the open-label, Phase 2 multiple-dose study of ISIS-SMN Rx and are continuing to receive treatment in an open-label extension (OLE) study.
In a recent development a team of 30 Spanish surgeons have succeeded in a World's first full face transplant. The patient had accidentally injured a large part of his face with a shotgun five years ago. This had left him disfigured an unable to breathe, swallow or talk properly. He has undergone nine unsuccessful operations before this operation was planned. In this operation he received the whole of his facial skin, muscles, nose, lips, teeth and cheek bones from a donor in a 22 hour operation at the Vall d'Hebron University Hospital on 20th March. He is on his way to recovery now. This is not the first face transplant but the first full face transplant and also the most complex of its kind.
Aperio Technologies, Inc., (Aperio), a global leader in digital pathology for the healthcare and life sciences industry, and HistoRx, Inc., (HistoRx), a leader in the emerging field of tissue-based assays for targeted patient treatment, have entered into a partnership to provide an integrated solution for whole-slide imaging with fluorescence.
Teva Pharmaceutical Industries Ltd. and OncoGenex Pharmaceuticals, Inc. announced today that they have entered into a global license and collaboration agreement to develop and commercialize OGX-011, as well as an agreement to purchase shares in OncoGenex. OGX-011 is a Phase III cancer therapy designed to inhibit cancer treatment resistance.
› Verified 4 days ago
Mrs. Nina Marie Perez Jackson, MOT,OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1311 Granite Canyon Rd, Livermore, CO 80536 Phone: 970-416-1398 Fax: 970-482-8397 |